8:20 AM
 | 
Feb 09, 2018
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Shield's Feraccru misses in Phase III for anemia

Shield Therapeutics plc (LSE:STX) reported that Feraccru ferric maltol missed the primary endpoint in the U.S. Phase III AEGIS-CKD trial to treat iron deficiency anemia (IDA) in patients with non-dialysis-dependent chronic kidney disease (CKD).

On the 168-patient trial's primary endpoint, twice-daily oral 30 mg Feraccru failed to significantly improve hemoglobin levels from baseline to week 16 vs. placebo (0.45 vs. 0.15 g/dL, p=0.1686). Secondary endpoints in the trial...

Read the full 317 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >